Intervening along the spectrum of tuberculosis: meeting report from the World TB Day nanosymposium in the Institute of Infectious Disease and Molecular Medicine at the University of Cape Town

Gates Open Research

article

Sabelo Hadebe¹  Melissa Chengalroyen²  Reto Guler¹  Kehilwe Nakedi⁵  Anastasia Koch²  Mohau Makatsa⁶  Muki Shey⁴  Suraj P. Parihar⁴  Bryan Bryson⁷  Mohlopheni J. Marakalala⁸  Hlumani Ndlovu⁵ 

[1] Division of Immunology and South African Medical Research Council ,(SAMRC) Immunology of Infectious Diseases, Department of Pathology, Faculty of Health Sciences, Institute of Infectious Diseases and Molecular Medicine;SAMRC/NHLS/UCT Molecular Mycobacteriology Research Unit, Molecular Mycobacteriology unit, Division of Medical Microbiology, Department of Pathology, Faculty of Health Sciences, Institute of Infectious Disease and Molecular Medicine based ,(IDM), University of Cape Town;Department of Pathology, Faculty of Health Sciences, University of Cape Town, International Centre for Genetic Engineering and Biotechnology;Wellcome Centre for Infectious Diseases Research in Africa ,(CIDRI-Africa), Institute of Infectious Diseases and Molecular Medicine ,(IDM), University of Cape Town;Division of Chemical and Systems Biology, Department of Integrative Biomedical Sciences, Faculty of Health Sciences, Institute of Infectious Diseases and Molecular Medicine, University of Cape Town;Division of Medical Virology, Department of Pathology, Faculty of Health Sciences, Institute of Infectious Diseases and Molecular Medicine, University of Cape Town;MIT Biological Engineering, Ragon Institute of MGH;Africa Health Research Institute;Division of Infection and Immunity, University College London

关键词: Tuberculosis;    TB/HIV co-infections;    Host directed Therapies;    transmission;    new tools;   

DOI  :  10.12688/gatesopenres.13035.4

学科分类：电子与电气工程

来源: American Journal Of Pharmtech Research

【 摘 要 】

Tuberculosis (TB), caused by the highly infectious Mycobacterium tuberculosis, remains a leading cause of death worldwide, with an estimated 1.6 million associated deaths reported in 2017. In South Africa, an estimated 322,000 (range 230,000-428,000) people were infected with TB in 2017, and a quarter of them lost their lives due to the disease. Bacille Calmette-Guérin (BCG) remains the only effective vaccine against disseminated TB, but its inability to confer complete protection against pulmonary TB in adolescents and adults calls for an urgent need to develop new and better vaccines. There is also a need to identify markers of disease protection and develop novel drugs. It is within this backdrop that we convened a nanosymposium at the Institute of Infectious Disease and Molecular Medicine at the University of Cape Town to commemorate World TB Day and showcase recent findings generated by early career scientists in the institute. The speakers spoke on four broad topics: identification of novel drug targets, development of host-directed drug therapies, transmission of TB and immunology of TB/HIV co-infections.

【 授权许可】

CC BY